Search

// Anbang He 1,2,* , Rong Hu 1,* , Zhicong Chen 2,3,* , Xinhui Liao 1,* , Jianfa Li 2,3 , Dailian Wang 2,4 , Zhaojie Lv 1 , Yuchen Liu 1,2 , Feng Wang 1 and Hongbing Mei 1,2 1 Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China 2 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China 3 Shantou University Medical College, Shantou, Guangdong, China 4 Guangzhou Medical University, Guangzhou, Guangdong, China * These authors have contributed equally to this work Correspondence to: Feng Wang, email: // Hongbing Mei, email: // Keywords : UCA1, lncRNA, prognosis, survival, lymph node metastasis Received : July 15, 2016 Accepted : September 21, 2016 Published : October 04, 2016 Abstract Accumulating evidences indicated that UCA1 expression was up-regulated in various cancers, and high UCA1 expression was correlated with metastasis and prognosis. This meta-analysis collected all eligible studies and explored the relationships between UCA1 expression and lymph node metastasis (LNM) or overall survival (OS). Literature collection was performed by using electronic databases PubMed, Cochrane Library, and Web of Science (up to June 13, 2016). According to the inclusion and exclusion criteria, twelve studies were included in the meta-analysis. The result showed that high UCA1 expression was correlated with more LNM (OR=2.50, 95 %CI: 1.58-3.96, p

// Jiangeng Yang 1, 2 , Yuchen Liu 1, 2 , Anbang He 1, 2, 3 , Yuhan Liu 1 , Jianting Wu 1 , Xinhui Liao 1 , Zhaojie Lv 1 , Feng Wang 1 and Hongbing Mei 1, 2 1 Department of Urology, Shenzhen Second People’s Hospital, Clinical Institute of Guangzhou Medical University, Shenzhen, China 2 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China 3 Anhui Medical University, Anhui, China Correspondence to: Hongbing Mei, email: hbmei68@163.com Keywords: microRNA, urothelial carcinoma, cyclin-dependent kinase inhibitor 2B Received: December 28, 2016 Accepted: July 06, 2017 Published: August 03, 2017 ABSTRACT Background and Objectives: Hsa-miR-429 is increased in bladder cancer. Its roles in bladder cancer are poorly understood. Methods: The expression levels of hsa-miR-429 and cyclin-dependent kinase inhibitor 2B (CDKN2B) were determined using Real-Time qPCR in a total of 50 patients with bladder cancer. Bladder cancer T24 and 5637 cells were transfected CDKN2B siRNA or hsa-miR-429 mimic. CDKN2B expression levels after transfection were detected by Real-Time qPCR and Western blot assay respectively. Binding sites between hsa-miR-429 and 3’-untranslated region of CDKN2B were confirmed by Dual luciferase reporter assay. Cell proliferation was evaluated using MTT and EdU assays. Cell apoptosis was determined using ELISA assay. Results: Higher hsa-miR-429 expression levels were associated with higher tumor grade and stage. All patients with low hsa-miR-429 expression survived 5 years, while with high hsa-miR-429 expression, only 58% survived. Hsa-miR-429 and CDKN2B were inversely expressed in bladder cancer. Hsa-miR-429 mimic decreased the expression of CDKN2B at both mRNA and protein levels. The binding site was confirmed between hsa-miR-429 and 3’-untranslated region of CDKN2B. Up-regulation of hsa-miR-429 or down-regulation of CDKN2B promoted cell growth and decreased apoptosis. Conclusions: Our data suggest a mechanism for hsa-miR-429 to play oncogenic roles via inhibiting CDKN2B.